pretickt

Is IQV a good stock to buy?

IQVIA Holdings Inc. · end-of-day data as of Nov 13, 2026

IQVIA
IQV · $43.69B
$265.12-2.2%
Nov 13, 2026 · close
$240$260$280SepOctNov9:3016:003 months +10.5%Nov 13 · close
▲ 6
  • PT$283.15 +6.8%
  • ConsensusBuy · 20
  • FCF yield+4.8%
  • News
  • Trendbullish
  • Sector▲ +15.9%
Neutral
  • Earnings in83d
  • P/E32.2x
  • RSI46
  • Support-2.7%
  • Resistance+3.9%
  • Off 52w high-6.8%
  • Volume1.4x
  • Bollingerlower half
  • P/E vs sector0.0%
  • 52w range$155–$285
  • ATR+3.4%
  • Off ATH-7.2%
  • MAs2 of 4
▼ 3
  • P/E vs own+21.0%
  • Insiders-$1.94M
  • MACD-0.40

Updates with the 15-min delayed price. Not a forecast or investment advice.

Is IQVIA a good stock to buy?

IQVIA is strong on 3 of the 5 questions about the business; weak on advantage. The price is high: 32.2 times its earnings, above its 3-year median of 26.8 (Nov 13, 2026). pretickt does not say whether to buy or sell.

  1. Demand steady
  2. Advantage easy to copy
  3. Economics profits growing
  4. Execution delivers
  5. Fragility sturdy
  6. Price expensive
DemandDo people want more of what it sells?steady

IQV sales growth revenue growth

+4%a year, for the last 3 years

IQVIA's sales grew 4% a year for 3 years, to $16.31B in fiscal 2025.

IQV analysts' forecast revenue estimates

+7%the sales they expect next fiscal year, on the last

Analysts expect IQVIA's sales to grow 7% to $17.48B in fiscal 2026 (14 analysts).

IQV competitors

pretickt analysis+9%its sales in 12 months, on a year before

IQVIA's sales grew 9% in the 12 months to Sep 30, 2026, faster than Agilent (+9%) and Mettler-Toledo (+7%), slower than Waters (+81%) and Natera (+37%).

IQV sales by business revenue by segment

55%of its sales from Research And Development Solutions

Research And Development Solutions brought IQVIA 55% of its sales in fiscal 2025; Technology And Analytics Solutions 41%.

Advantage moatIs it hard to copy?easy to copy

IQV margin on each sale gross margin

26%left after making the product

IQVIA kept 26% of each sale after making the product in the 12 months to Sep 30, 2026; its competitors' median is 56%.

EconomicsDoes it make good money?profits growing

IQV cash generated free cash flow

$2.08Bcash left after investing, last 12 months

IQVIA generated $2.08B of free cash flow in the 12 months to Sep 30, 2026, more than its reported profit.

IQV profit per share

+5%in its last fiscal year

IQVIA's earnings per share grew 5% in fiscal 2025, to $7.86.

ExecutionDoes it deliver what it promises?delivers

IQV earnings vs estimates

8 of 8quarters above the analysts' estimate

IQVIA beat the analysts' profit estimate in each of its last 8 quarters, the latest on Oct 27, 2026.

IQV insider selling

-$39.26Msold, net, by its executives in 12 months

IQVIA's executives and directors sold a net $39.26M of shares in the 12 months to Nov 13, 2026; none bought.

IQV number of employees

+6%more people in a year

IQVIA had 93,000 employees at the end of fiscal 2025, 6% more than a year before.

IQV CEO pay

$28.13Mfor fiscal 2025, 72% of it in stock and options

IQVIA paid its CEO $28.13M for fiscal 2025, 72% of it in stock and options.

Fragility risksCould something break it?sturdy

IQV financial health Altman Z-score

2.3Altman Z-score, safe above 3

IQVIA's Altman Z-score is 2.3 (Nov 13, 2026), between 1.8 and 3, the grey zone.

IQV biggest customers

under 10%of sales from any one customer

No customer made 10% of IQVIA's sales in fiscal 2025.

Price valuationIs the price reasonable?expensive

IQV price vs profit P/E ratio

32.2×a year's earnings

IQVIA's P/E ratio is 32.2 (Nov 13, 2026), above its 3-year median of 26.8.

IQV price vs competitors

pretickt analysis32.2×a year's earnings, against its competitors

Investors pay 32.2 times IQVIA's earnings (Nov 13, 2026), less than for Waters (197.5), Mettler-Toledo (37.7) or Agilent (34.2).

IQV analysts' target price target

+7%to their average target

Analysts' average price target for IQVIA is $283, 7% above the Nov 13, 2026 close of $265.12.

IQV growth priced in fair value

pretickt analysis+8%a year, for ten years, to be worth the price

At $265.12 a share, IQVIA's free cash flow must grow about 8% a year for ten years to be worth the price (Nov 13, 2026).

What is IQVIA's P/E ratio?

IQVIA's P/E ratio is 32.2 (Nov 13, 2026), above its 3-year median of 26.8. Investors pay 32.2 times IQVIA's earnings (Nov 13, 2026), less than for Waters (197.5), Mettler-Toledo (37.7) or Agilent (34.2).

Who are IQVIA's biggest competitors?

pretickt compares IQVIA with Waters, Natera, Agilent and Mettler-Toledo. IQVIA's sales grew 9% in the 12 months to Sep 30, 2026, faster than Agilent (+9%) and Mettler-Toledo (+7%), slower than Waters (+81%) and Natera (+37%).

Are insiders selling IQVIA stock?

IQVIA's executives and directors sold a net $39.26M of shares in the 12 months to Nov 13, 2026; none bought.

How does IQVIA make money?

Research And Development Solutions brought IQVIA 55% of its sales in fiscal 2025; Technology And Analytics Solutions 41%.

How many employees does IQVIA have?

IQVIA had 93,000 employees at the end of fiscal 2025, 6% more than a year before.

Who are IQVIA's biggest customers?

No customer made 10% of IQVIA's sales in fiscal 2025.

From the companies' statements (FMP), their filings read by pretickt, the analysts and the insiders, as of Nov 13, 2026. Each card says what a fact means for its question, never what to do with the stock: for information only, not investment advice.